GARVAN INSTITUTE OF MEDICAL RESEARCH
🇦🇺Australia
- Country
- 🇦🇺Australia
- Ownership
- -
- Established
- 1963-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.garvan.org.au
Clinical Trials
26
Active:1
Completed:12
Trial Phases
5 Phases
Phase 1:2
Phase 2:6
Phase 3:3
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (23 trials with phase data)• Click on a phase to view related trials
Not Applicable
10 (43.5%)Phase 2
6 (26.1%)Phase 3
3 (13.0%)Phase 1
2 (8.7%)Phase 4
2 (8.7%)Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes
Phase 2
Not yet recruiting
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Drug: Tirzepatide 2.5mg weeklyDrug: Placebo injection (normal saline)
- First Posted Date
- 2025-02-11
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Garvan Institute of Medical Research
- Target Recruit Count
- 20
- Registration Number
- NCT06820281
- Locations
- 🇦🇺
Garvan Institute of Medical Research, Sydney, New South Wales, Australia
Preventing Cognitive Decline with Metformin
Phase 3
Active, not recruiting
- Conditions
- Cognitive Decline
- Interventions
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Garvan Institute of Medical Research
- Target Recruit Count
- 242
- Registration Number
- NCT04511416
- Locations
- 🇦🇺
Garvan Institute of Medical Research, Sydney, New South Wales, Australia
Personalised Medicine in Pre-diabetes and Early Type 2 Diabetes
Not Applicable
Completed
- Conditions
- Pre DiabetesType 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Garvan Institute of Medical Research
- Target Recruit Count
- 138
- Registration Number
- NCT03558867
- Locations
- 🇦🇺
Garvan Institute of Medical Research, Sydney, New South Wales, Australia
Optimising Health in Type 1 Diabetes
Not Applicable
Completed
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Garvan Institute of Medical Research
- Target Recruit Count
- 13
- Registration Number
- NCT02903615
- Locations
- 🇦🇺
professor Katherine Samaras, Sydney, New South Wales, Australia
🇦🇺Garvan Institute to Medical Research, Sydney, Australia
Alkaline Diet for Insulin Sensitivity
Not Applicable
Completed
- Conditions
- Type 2 Diabetes MellitusDysglycemia
- Interventions
- Drug: Sodium Bicarbonate Oral CapsuleDrug: Placebo
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Garvan Institute of Medical Research
- Target Recruit Count
- 32
- Registration Number
- NCT02501343
- Locations
- 🇦🇺
Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia
- Prev
- 1
- 2
- 3
- Next
News
No news found